ClinicalTrials.gg
TerminatedNCT05398263SUNRISEUpdated Jun 18, 2026Results posted

Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

A Phase 3 interventional study of Tezepelumab and Placebo in Asthma, sponsored by AstraZeneca. Terminated at 64 sites in 12 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was discontinued due to slow recruitment, resulting from evolving clinical practices that reduced the use of maintenance oral corticosteroids for severe asthma treatment. The termination decision was not related to safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.

Enrollment
14th of 28
125 · median 121
Started
2022
with 3 others
Phase 3
16 of 28
4 open now
Registered
18th of 28
by date
Lead sponsor
16 of 28
AstraZeneca

Among the 28 studies testing tezepelumab in Asthma, this one is the 14th largest by enrollment, is one of 4 that started in 2022, is one of 16 in phase 3, and was the 18th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tezepelumab

tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing tezepelumab in Asthma, or all of them as a file.
02

Study summary

A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma

Read the detailed description

This is a multicentre, randomised, double-blind, placebo controlled, parallel group study designed to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma treated with maintenance OCS in combination with high dose inhaled corticosteroids (ICS) and long-acting β2 agonists (LABA), with or without other asthma controller therapies. Approximately 207 subjects will be randomized globally. Subjects will receive tezepelumab, or placebo, administered via subcutaneous injection using the accessorized pre-filled syringe (APFS), over a 28-week treatment period. The study also includes a post-treatment follow-up period of 12 weeks.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Severe Asthma
  • Oral Corticosteroid Dependent Asthma
  • Tezepelumab
  • Phase 3 Study
  • Reducing Oral Corticosteroid
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria:

  1. Participant must be 18 to 80 years of age.
  2. Documented physician-diagnosed asthma for at least 12 months prior to Visit 1.
  3. Participants must have received a physician-prescribed medium- or high-dose ICS for at least 12 months prior to Visit 1.
  4. Participants must have received physician prescribed LABA and high dose ICS for at least 3 months prior to Visit 1.
  5. Additional maintenance asthma controller medications are allowed. The use of these medications must be documented for at least 3 months prior to Visit 1.
  6. Participants must have received OCS for the treatment of asthma for at least 6 months prior to Visit 1 and on a stable dose of between ≥7.5 to ≤ 30 mg (prednisone or prednisolone) daily or daily equivalent for at least 1 month prior to Visit 1.
  7. Morning pre- bronchodilator (BD) must be \< 80% predicted normal at Visit 1 or Visit 2.
  8. Evidence of asthma as documented by either:

    a)Post-BD responsiveness test result: FEV1 ≥12% and ≥200 mL documented either in the previous 60 months prior to or at Visit 1 or at Visit 2 or at Visit 3; OR b)Airway hyperresponsiveness (methacholine: provocative concentration that causes a positive reaction [PC20] of \<8 mg/mL) documented in the 60 months prior to Visit 1.

  9. Blood eosinophils at Visit 1 ≥150 cells/μL or documented EOS ≥300 cells/μL within 12 months prior to Visit 1.
  10. Participants must have a history of at least 1 asthma exacerbation event within 24 months prior to Visit 1.
  11. Participants must have received the optimised OCS dose for at least 2 weeks prior to randomisation.

Other inclusion criteria per protocol apply.

Main exclusion criteria

  1. Any pulmonary disease other than asthma.
  2. Any disorder that is not stable in the opinion of the Investigator and could: a. Affect the safety of the participant throughout the study; b. Influence the findings of the study or the interpretation; c. Impede the participant's ability to complete the entire duration of study.
  3. History of cancer: a. Participants who have had basal cell carcinoma, localised squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible to participate in the study provided that curative therapy was completed at least 12 months prior to Visit 1; b. Participants who have had other are eligible provided that curative therapy was completed at least 5 years prior to Visit 1.
  4. Asthma exacerbation, requiring use of systemic or increase in the maintenance dose of OCS finalized within 30 days prior to Visit 1.
  5. Clinically significant infection requiring treatment with systemic antibiotics or antiviral medications finalized \< 2 weeks before Visit 1 or during the run-in period.
  6. Participants with evidence of active COVID-19 infection during run-in period and optimisation.
  7. A helminth infection diagnosed within 6 months prior to Visit 1 that has not been treated with, or has failed to respond to, standard of care therapy.
  8. A participant who is on SABA maintenance treatment within 30 days prior to Visit 1.
  9. Current smokers or participants with smoking history ≥ 10 pack-years and participants using vaping products, including electronic cigarettes. Former smokers with a smoking history of \<10 pack years and users of vaping or e-cigarette products must have stopped for at least 6 months prior to Visit 1 to be eligible.
  10. Receipt of any marketed or biologic agent within 4 months or 5 half-lives (whichever is longer) prior to Visit 1 or receipt of any investigational non-biologic agent within 30 days or 5 half-lives (whichever is longer) prior to Visit 1.
  11. COVID-19 vaccination within 28 days prior to randomisation.
  12. Tuberculosis requiring treatment within the 12 months prior to Visit 1.
  13. During the optimisation period, asthma control reached at an OCS dose of \<7.5 mg or >30 mg and/or 3 consecutive dose reductions after which asthma control was still obtained.

Other exclusion criteria per protocol apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Tezepelumab

    Tezepelumab subcutaneous injection, in an accessorised pre-filled syringe.

    Biological: Tezepelumab

  • Placebo comparator
    Placebo

    Placebo subcutaneous injection, in an accessorised pre-filled syringe.

    Other: Placebo

Interventions

  • BiologicalTezepelumab

    Tezepelumab subcutaneous injection

  • OtherPlacebo

    Placebo subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects by Categorised Percent Reduction From Baseline in the Daily Maintenance OCS Dose at Week 28 Whilst Maintaining Asthma Control.

    Proportion of subjects by categorised percent reduction from baseline at Week 28. Percent change from baseline is defined as {final dose-baseline dose)/baseline dose}\*100%, and the categories of percent change from baseline in daily OCS dose are defined as: ≥90% to ≤100% reduction, ≥75% to \<90% reduction, ≥50% to \<75% reduction, \>0% to \<50% reduction, and, no change or any increase.

    Time frame: Baseline to Week 28

Secondary outcomes

  1. Change From Baseline in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) at Week 28

    Change from baseline in pre-BD FEV1 at Week 28. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.

    Time frame: Baseline to Week 28

  2. Proportion of Subjects With 100% Reduction From Baseline in Daily OCS Dose at Week 28

    Proportion of subjects with 100% reduction from baseline in daily OCS dose at Week 28. Percent change from baseline is defined as {(final dose-baseline dose)/baseline dose}\*100%.

    Time frame: Baseline to Week 28

  3. Proportion of Subjects With Daily OCS Dose ≤5 mg at Week 28

    Proportion of subjects with daily OCS dose ≤5 mg at Week 28.

    Time frame: Week 28

  4. Proportion of Subjects With ≥50% Reduction From Baseline in Daily OCS Dose at Week 28

    Proportion of subjects with ≥50% reduction from baseline in daily OCS dose at Week 28. Percent change from baseline is defined as {(final dose-baseline dose)/baseline dose}\*100%.

    Time frame: Baseline to Week 28

  5. Annualised Asthma Exacerbation Rate (AAER) Over 28 Weeks

    The annualized exacerbation rate is based on exacerbations reported by the investigator in the eCRF over 28 weeks.

    Time frame: Baseline to Week 28

  6. Proportion of Subjects With >= 1 Asthma Exacerbation

    Time to first asthma exacerbation, presented as proportion of subjects with at least one asthma exacerbation as reported by the investigator in the eCRF

    Time frame: Baseline to Week 28

  7. Change From Baseline in Asthma Control Questionnaire 6 (ACQ-6) Score at Week 28

    Change from baseline in ACQ-6 as compared to placebo at Week 28. The ACQ-6 captures asthma symptoms and short-acting β2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.

    Time frame: Baseline to Week 28

  8. Change From Baseline in Weekly Mean Home Peak Expiratory Flow (PEF) (Morning and Evening) at Week 28

    Change from baseline in weekly mean morning and evening peak expiratory flow (PEF) as compared to placebo at Week 28. Home PEF testing will be performed by the subject in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Each timepoint is calculated as weekly.

    Time frame: Baseline to Week 28

  9. Change From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(s)+12) Total Score at Week 28

    Change from baseline in AQLQ(S)+12 as compared to placebo at Week 28. The AQLQ(S)+12 is a questionnaire that measures the health-related quality of life experienced by asthma subjects. The total score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment).

    Time frame: Baseline to Week 28

  10. Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Score at Week 28

    Change from baseline in SGRQ as compared to placebo at Week 28. The questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The total score indicates the impact of disease on overall health status. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible health status and 0 indicates the best possible health status.

    Time frame: Baseline to Week 28

  11. Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 28

    Change from baseline in fractional exhaled nitric oxide (FeNO) at Week 28.

    Time frame: Baseline to Week 28

  12. Change From Baseline in Peripheral Blood Eosinophils at Week 28

    Change from baseline in blood eosinophil counts at Week 28.

    Time frame: Baseline to Week 28

  13. Change From Baseline in Total Serum Immunoglobulin E (IgE) at Week 28

    Change from baseline in total serum IgE at Week 28.

    Time frame: Baseline to Week 28

  14. PK: Serum Trough Concentrations at Week 0, 12 and 28

    Pharmacokinetics samples are collected at baseline and at Week 12 prior to study intervention administration, and at Week 28 (End of Treatment visit).

    Time frame: Baseline, Week 12 and Week 28

  15. Immunogenicity: Incidence of Anti-drug Antibodies (ADA) at Week 0, 12, 28, and 40

    Immunogenicity samples are collected at baseline and at Week 12 prior to study intervention administration, at Week 28 (End of Treatment visit) and at Week 40 (Follow-up visit). Persistently positive is defined as positive at \>=2 post baseline assessments (with \>=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Treatment boosted ADA defined as baseline positive ADA that was boosted to a 4 fold or higher level following treatment. Treatment emergent ADA defined as sum of treatment induced ADA and treatment boosted ADA.

    Time frame: Baseline to Week 40

07

Results

Posted Jun 18, 2026

Participant flow

The study was conducted at 64 centres in 12 countries. Between 9AUG2022 and 29NOV2024, 250 subjects were screened; 125 were randomized and treated, and 125 were not randomized mainly due to screen failures. Four participants (1 tezepelumab, 2 placebo, 1 screen failure) from one site were excluded for quality issues, so 122 randomized participants were analysed. The sponsor terminated the study early due to recruitment challenges.

Participant flow — Overall Study
MilestoneTezepelumabPlacebo
Started8441
Completed5930
Not completed2511
Withdrew: Adverse event10
Withdrew: Death21
Withdrew: Lost to follow-up20
Withdrew: Study terminated by sponsor187
Withdrew: Withdrawal by subject10
Withdrew: End of study due to low compliance by participant01
Withdrew: Site quality issues12

Outcome measures

PrimaryProportion of Subjects by Categorised Percent Reduction From Baseline in the Daily Maintenance OCS Dose at Week 28 Whilst Maintaining Asthma Control.

Proportion of subjects by categorised percent reduction from baseline at Week 28. Percent change from baseline is defined as {final dose-baseline dose)/baseline dose}\*100%, and the categories of percent change from baseline in daily OCS dose are defined as: ≥90% to ≤100% reduction, ≥75% to \<90% reduction, ≥50% to \<75% reduction, \>0% to \<50% reduction, and, no change or any increase.

Time frame:
Baseline to Week 28
Reported as:
Count of participants · Participants
Proportion of Subjects by Categorised Percent Reduction From Baseline in the Daily Maintenance OCS Dose at Week 28 Whilst Maintaining Asthma Control.
ParticipantsTezepelumabPlacebo
>=90% to <=100% reduction308
>=75% to <90% reduction73
>=50% to <75% reduction206
>0% to <50% reduction126
no change or any increase1416
Statistical analysis
  • Tezepelumab vs Placebo · Proportional odds model · p = 0.003 · Cumulative odds ratio: 2.93 · 95% CI 1.43 to 6.03A cumulative odds ratio greater than one favours Tezepelumab.
SecondaryChange From Baseline in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) at Week 28

Change from baseline in pre-BD FEV1 at Week 28. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.

Time frame:
Baseline to Week 28
Reported as:
Mean · Litre
Change From Baseline in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) at Week 28
LitreTezepelumabPlacebo
Change From Baseline in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) at Week 280.240 ± 0.498-0.019 ± 0.310
SecondaryProportion of Subjects With 100% Reduction From Baseline in Daily OCS Dose at Week 28

Proportion of subjects with 100% reduction from baseline in daily OCS dose at Week 28. Percent change from baseline is defined as {(final dose-baseline dose)/baseline dose}\*100%.

Time frame:
Baseline to Week 28
Reported as:
Count of participants · Participants
Proportion of Subjects With 100% Reduction From Baseline in Daily OCS Dose at Week 28
ParticipantsTezepelumabPlacebo
Proportion of Subjects With 100% Reduction From Baseline in Daily OCS Dose at Week 28298
SecondaryProportion of Subjects With Daily OCS Dose ≤5 mg at Week 28

Proportion of subjects with daily OCS dose ≤5 mg at Week 28.

Time frame:
Week 28
Reported as:
Count of participants · Participants
Proportion of Subjects With Daily OCS Dose ≤5 mg at Week 28
ParticipantsTezepelumabPlacebo
Proportion of Subjects With Daily OCS Dose ≤5 mg at Week 284915
SecondaryProportion of Subjects With ≥50% Reduction From Baseline in Daily OCS Dose at Week 28

Proportion of subjects with ≥50% reduction from baseline in daily OCS dose at Week 28. Percent change from baseline is defined as {(final dose-baseline dose)/baseline dose}\*100%.

Time frame:
Baseline to Week 28
Reported as:
Count of participants · Participants
Proportion of Subjects With ≥50% Reduction From Baseline in Daily OCS Dose at Week 28
ParticipantsTezepelumabPlacebo
Proportion of Subjects With ≥50% Reduction From Baseline in Daily OCS Dose at Week 285717
SecondaryAnnualised Asthma Exacerbation Rate (AAER) Over 28 Weeks

The annualized exacerbation rate is based on exacerbations reported by the investigator in the eCRF over 28 weeks.

Time frame:
Baseline to Week 28
Reported as:
Number · Events per year
Annualised Asthma Exacerbation Rate (AAER) Over 28 Weeks
Events per yearTezepelumabPlacebo
Annualised Asthma Exacerbation Rate (AAER) Over 28 Weeks0.651.98
SecondaryProportion of Subjects With >= 1 Asthma Exacerbation

Time to first asthma exacerbation, presented as proportion of subjects with at least one asthma exacerbation as reported by the investigator in the eCRF

Time frame:
Baseline to Week 28
Reported as:
Count of participants · Participants
Proportion of Subjects With >= 1 Asthma Exacerbation
ParticipantsTezepelumabPlacebo
Proportion of Subjects With >= 1 Asthma Exacerbation2523
SecondaryChange From Baseline in Asthma Control Questionnaire 6 (ACQ-6) Score at Week 28

Change from baseline in ACQ-6 as compared to placebo at Week 28. The ACQ-6 captures asthma symptoms and short-acting β2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.

Time frame:
Baseline to Week 28
Reported as:
Mean · Score on a scale
Change From Baseline in Asthma Control Questionnaire 6 (ACQ-6) Score at Week 28
Score on a scaleTezepelumabPlacebo
Change From Baseline in Asthma Control Questionnaire 6 (ACQ-6) Score at Week 28-1.25 ± 1.14-0.59 ± 1.09
SecondaryChange From Baseline in Weekly Mean Home Peak Expiratory Flow (PEF) (Morning and Evening) at Week 28

Change from baseline in weekly mean morning and evening peak expiratory flow (PEF) as compared to placebo at Week 28. Home PEF testing will be performed by the subject in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Each timepoint is calculated as weekly.

Time frame:
Baseline to Week 28
Reported as:
Mean · L/min
Change From Baseline in Weekly Mean Home Peak Expiratory Flow (PEF) (Morning and Evening) at Week 28
L/minTezepelumabPlacebo
Weekly mean morning PEF27.4 ± 65.0-10.6 ± 56.9
Weekly mean evening PEF24.3 ± 70.3-12.4 ± 51.7
SecondaryChange From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(s)+12) Total Score at Week 28

Change from baseline in AQLQ(S)+12 as compared to placebo at Week 28. The AQLQ(S)+12 is a questionnaire that measures the health-related quality of life experienced by asthma subjects. The total score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment).

Time frame:
Baseline to Week 28
Reported as:
Mean · Scores on a scale
Change From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(s)+12) Total Score at Week 28
Scores on a scaleTezepelumabPlacebo
Change From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(s)+12) Total Score at Week 281.42 ± 1.330.44 ± 1.20
SecondaryChange From Baseline in St George's Respiratory Questionnaire (SGRQ) Score at Week 28

Change from baseline in SGRQ as compared to placebo at Week 28. The questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The total score indicates the impact of disease on overall health status. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible health status and 0 indicates the best possible health status.

Time frame:
Baseline to Week 28
Reported as:
Mean · Scores on a scale
Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Score at Week 28
Scores on a scaleTezepelumabPlacebo
Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Score at Week 28-22.09 ± 24.04-6.14 ± 24.29
SecondaryChange From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 28

Change from baseline in fractional exhaled nitric oxide (FeNO) at Week 28.

Time frame:
Baseline to Week 28
Reported as:
Mean · ppb
Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 28
ppbTezepelumabPlacebo
Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 28-14.0 ± 27.02.0 ± 21.9
SecondaryChange From Baseline in Peripheral Blood Eosinophils at Week 28

Change from baseline in blood eosinophil counts at Week 28.

Time frame:
Baseline to Week 28
Reported as:
Mean · cells/μL
Change From Baseline in Peripheral Blood Eosinophils at Week 28
cells/μLTezepelumabPlacebo
Change From Baseline in Peripheral Blood Eosinophils at Week 28-112.9 ± 314.2-79.2 ± 279.2
SecondaryChange From Baseline in Total Serum Immunoglobulin E (IgE) at Week 28

Change from baseline in total serum IgE at Week 28.

Time frame:
Baseline to Week 28
Reported as:
Mean · IU/mL
Change From Baseline in Total Serum Immunoglobulin E (IgE) at Week 28
IU/mLTezepelumabPlacebo
Change From Baseline in Total Serum Immunoglobulin E (IgE) at Week 28-50.006 ± 520.663-8.107 ± 195.584
SecondaryPK: Serum Trough Concentrations at Week 0, 12 and 28

Pharmacokinetics samples are collected at baseline and at Week 12 prior to study intervention administration, and at Week 28 (End of Treatment visit).

Time frame:
Baseline, Week 12 and Week 28
Reported as:
Geometric mean · μg/mL
PK: Serum Trough Concentrations at Week 0, 12 and 28
μg/mLTezepelumabPlacebo
Week 00 ± 0—
Week 1218.371 ± 50.59—
Week 2819.849 ± 55.23—
SecondaryImmunogenicity: Incidence of Anti-drug Antibodies (ADA) at Week 0, 12, 28, and 40

Immunogenicity samples are collected at baseline and at Week 12 prior to study intervention administration, at Week 28 (End of Treatment visit) and at Week 40 (Follow-up visit). Persistently positive is defined as positive at \>=2 post baseline assessments (with \>=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Treatment boosted ADA defined as baseline positive ADA that was boosted to a 4 fold or higher level following treatment. Treatment emergent ADA defined as sum of treatment induced ADA and treatment boosted ADA.

Time frame:
Baseline to Week 40
Reported as:
Count of participants · Participants
Immunogenicity: Incidence of Anti-drug Antibodies (ADA) at Week 0, 12, 28, and 40
ParticipantsTezepelumabPlacebo
ADA positive at baseline and/or post-baseline (ADA prevalence) [a]62
TE-ADA positive (ADA incidence) [b]31
Treatment-induced ADA positive [b]31
Treatment-boosted ADA positive [b]00
Non-TE-ADA positive [b]31
Both baseline and post-baseline positive [b]00
Only baseline positive [c]31
ADA persistently positive [b]20
ADA transiently positive [b]11
nAb positive at baseline and/or post-baseline (nAb prevalence) [a]10
Treatment-induced nAb positive (nAb incidence) [b]10

Adverse events

Collected over From the date of first dose of study intervention throughout the treatment period and including the follow-up period (i.e. up to Week 40).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tezepelumab2/83 (2.4%)7/83 (8.4%)33/83 (39.8%)
Placebo1/39 (2.6%)5/39 (12.8%)21/39 (53.8%)
Most frequent serious events
Most frequent serious events
EventTezepelumabPlacebo
AsthmaRespiratory, thoracic and mediastinal disorders2/833/39
TracheobronchitisInfections and infestations0/831/39
Cardiac arrestCardiac disorders0/831/39
Soft tissue infectionInfections and infestations1/830/39
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/830/39
MeningiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/830/39
Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/830/39
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/830/39
Sudden cardiac deathGeneral disorders1/830/39
PneumoniaInfections and infestations1/830/39
Most frequent other events
Showing 10 of 13
Most frequent other events
EventTezepelumabPlacebo
NasopharyngitisInfections and infestations11/837/39
HeadacheNervous system disorders2/834/39
BronchitisInfections and infestations2/834/39
Upper respiratory tract infectionInfections and infestations7/833/39
Urinary tract infectionInfections and infestations5/832/39
SinusitisInfections and infestations2/832/39
AnxietyPsychiatric disorders1/832/39
Oral candidiasisInfections and infestations3/832/39
FallInjury, poisoning and procedural complications3/831/39
Limb injuryInjury, poisoning and procedural complications3/830/39

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TezepelumabPlaceboTotal
<=18 years000
Between 18 and 65 years673299
>=65 years16723
Age, Continuous
Age, Continuous(Years)TezepelumabPlaceboTotal
Mean51.6 ± 12.753.6 ± 13.052.2 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)TezepelumabPlaceboTotal
Female652792
Male181230
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TezepelumabPlaceboTotal
American Indian or Alaska Native314
Asian14519
Black or African American112
Native Hawaiian or other Pacific Islander000
White422567
Other/Multiple race21627
Missing213
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TezepelumabPlaceboTotal
Hispanic or Latino422163
Not Hispanic or Latino411859
08

Study locations

64 sites
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Denver, Colorado 80206, United States
  • Research Site
    Newark, Delaware 19713, United States
  • Research Site
    Hialeah, Florida 33016, United States
  • Research Site
    Miami Lakes, Florida 33014, United States
  • Research Site
    Lincoln, Nebraska 68510, United States
  • Research Site
    The Bronx, New York 10459, United States
  • Research Site
    El Paso, Texas 79902, United States
  • Research Site
    Kingwood, Texas 77339, United States
  • Research Site
    Botucatu, 18618-686, Brazil
  • Research Site
    Curitiba, 80730-150, Brazil
  • Research Site
    Porto Alegre, 90035074, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Salvador, 40060-330, Brazil
  • Research Site
    São Bernardo do Campo, 09715090, Brazil
  • Research Site
    São Paulo, 01223-001, Brazil
  • Research Site
    Sorocaba, 18040-425, Brazil
  • Research Site
    Ajax, Ontario L1S 2J5, Canada
  • Research Site
    Québec, Quebec G1V4G5, Canada
  • Research Site
    Chile, 7770484, Chile
  • Research Site
    Curicó, 3341643, Chile
  • Research Site
    Santiago, 7500010, Chile
  • Research Site
    Santiago, 7500588, Chile
  • Research Site
    Santiago, 7500691, Chile
  • Research Site
    Santiago, 7500698, Chile
  • Research Site
    Santiago, 7750495, Chile
  • Research Site
    Santiago, 8241479, Chile
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Hradec Králové, 500 05, Czechia
  • Research Site
    Jindřichův Hradec, 377 01, Czechia
  • Research Site
    Miroslav, 671 72, Czechia
  • Research Site
    Olomouc, 779 00, Czechia
  • Research Site
    Ostrava, 700 30, Czechia
  • Research Site
    Ajmer, 305001, India
  • Research Site
    Kanpur, 208002, India
  • Research Site
    Vadodara, 390022, India
  • Research Site
    Guadalajara, 44100, Mexico
  • Research Site
    Guadalajara, 44130, Mexico
  • Research Site
    Guadalajara, 44200, Mexico
  • Research Site
    Mexico City, 0 3100, Mexico
  • Research Site
    Monterrey, 64460, Mexico
  • Research Site
    San Luis Potosí City, 78250, Mexico
  • Research Site
    Veracruz, 91910, Mexico
  • Research Site
    Lima, 15046, Peru
  • Research Site
    Bialystok, 15-704, Poland
  • Research Site
    Bychawa, 23100, Poland
  • Research Site
    Bydgoszcz, 85-231, Poland
  • Research Site
    Chęciny, 26-060, Poland
  • Research Site
    Grudziądz, 86-300, Poland
  • Research Site
    Ostrowiec Świętokrzyski, 27-400, Poland
  • Research Site
    Poznan, 61-578, Poland
  • Research Site
    Rzeszów, 35-205, Poland
  • Research Site
    Sosnowiec, 41-208, Poland
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Seoul, 07061, South Korea
  • Research Site
    Seoul, 143-729, South Korea
  • Research Site
    Suwon, 16499, South Korea
  • Research Site
    Bang Kra So, 11000, Thailand
  • Research Site
    Bangkok, 10330, Thailand
  • Research Site
    Hat Yai, 90110, Thailand
  • Research Site
    Ankara, 06620, Turkey (Türkiye)
  • Research Site
    Bursa, 16059, Turkey (Türkiye)
  • Research Site
    Istanbul, 34899, Turkey (Türkiye)
  • Research Site
    Izmir, 35040, Turkey (Türkiye)
09

References and documents

Publications

  • Wechsler ME, Brightling CE, Brusselle G, Caminati M, Soler T, Gonzalez EM, Nakwan N, Capala-Szczurko I, Hunter G, Almqvist G, Lal H, Kabelis P, Scrigner P, Matsunaga Y, Molfino N, Ponnarambil SS; SUNRISE study investigators. Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial. Lancet Respir Med. 2026 Jun;14(6):481-492. doi: 10.1016/S2213-2600(26)00076-7. Epub 2026 May 18. PubMed 42150582 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluatedas per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes,indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level datain an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Mar 2025, 31 months.

Results were first posted in Jun 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2022
First posted
May 31, 2022
StartActual
Aug 9, 2022
Primary completionActual
Mar 24, 2025
CompletionActual
Mar 24, 2025
Results first posted
Jun 18, 2026
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05398263
Lead sponsor
AstraZeneca
Collaborators
Amgen
Responsible party
Sponsor
First posted
May 31, 2022
Start date
Aug 9, 2022
Primary completion
Mar 24, 2025
Completion
Mar 24, 2025
Results posted
Jun 18, 2026
Last update
Jun 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion